Regulation of lung cancer metastasis through transcriptional control of the Golgi apparatus

通过高尔基体的转录控制调节肺癌转移

基本信息

  • 批准号:
    10062880
  • 负责人:
  • 金额:
    $ 36.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-12-01 至 2022-10-31
  • 项目状态:
    已结题

项目摘要

Our goal is to better understand the biologic basis for metastasis of KRAS-mutant lung cancer (KMLC) and to develop novel therapeutic approaches on the basis of that improved understanding. Progress in this area could potentially have a tremendous public health impact because metastasis is the primary cause of death from lung cancer, and there are currently few effective therapeutic options for KMLC. Towards that goal, we generated KP mice, which develop metastatic lung adenocarcinoma owing to the co-expression of K-rasG12D and p53R172H. Our preliminary results show that Zeb1, a transcriptional driver of metastasis in KP mice and predictor of poor clinical outcome in multiple epithelial tumor types, caused the Golgi organelle to become more compact and centralized, form ribbon-linked cisternal stacks, and stimulate vesicle trafficking in the anterograde direction. ZEB1 increased the expression of PAQR11, a Golgi scaffolding protein that was required for ZEB1-induced Golgi organelle integrity and tumor cell metastatic properties. In pull-down assays, the scaffolding domain of PAQR11 bound to vesicle coatomer proteins, GTPases that regulate vesicle budding and tethering, and dynein motor proteins that transport cargo along microtubules towards the cell's center. PAQR11 depletion reduced the migratory, invasive, and metastatic activities of lung adenocarcinoma cells derived from KP mice and human KMLC cells. High intra-tumoral PAQR11 levels predicted shorter survival in a compendium of 11 independent human lung cancer cohorts and a pan-cancer analysis of over 30 tumor types. On the basis of our preliminary results, we hypothesize that KMLCs gain metastatic potential through transcriptional control of the Golgi apparatus. To test this hypothesis, we propose two Specific Aims. In the first Aim, we will determine whether PAQR11 facilitates the dynein-mediated transport of Golgi mini-stacks and ribbon-linking and stacking of cisternae to create a centralized Golgi complex that drives anterograde vesicle trafficking and promotes tumor cell motility. In the second Aim, we will determine the extent to which ectopic PAQR11 expression promotes the metastasis of spontaneously occurring KMLCs. If our hypothesis is correct, these findings will advance our understanding of the mechanisms by which KMLC cells gain metastatic propensity and provide researchers in the field with new tools to investigate Golgi dynamics in tumor cells in the native microenvironment of the lung, an improved understanding of the underlying causes of lung adenocarcinoma metastasis, and a basis for investigating agents that target mediators of Zeb1 in clinical trials to prevent KMLC metastasis.
我们的目标是更好地了解KRAS突变肺癌(KMLC)转移的生物学基础和 在这种理解的基础上开发新的治疗方法。这一领域的进展可能 可能会对公众健康造成巨大影响,因为转移是 肺癌,目前对KMLC几乎没有有效的治疗选择。为了实现这一目标,我们 K-RasG12D共表达致小鼠肺腺癌转移 和p53R172H。我们的初步结果表明,ZEB1是KP小鼠转移的转录驱动因素,并且 多种上皮性肿瘤类型临床预后不良的预测因子,导致高尔基细胞器 更紧凑和集中,形成带状连接的脑池堆叠,并刺激囊泡在 顺行方向。ZEB1增加PAQR11的表达,PAQR11是高尔基体支架蛋白 ZEB1诱导的高尔基细胞器完整性和肿瘤细胞转移特性所必需的。在下拉分析中, PAQR11的支架结构域与囊泡共瘤蛋白结合,GTP酶调节囊泡萌发 以及沿着微管将货物运送到细胞中心的动力蛋白。 PAQR11缺失降低肺腺癌细胞的迁移、侵袭和转移活性 来源于KP小鼠和人KMLC细胞。高水平的肿瘤内PAQR11预示着较短的生存期 11个独立的人类肺癌队列的概要和对30多种肿瘤类型的泛癌分析。 根据我们的初步结果,我们假设KMLCs通过以下途径获得转移潜能 高尔基体的转录调控。 为了检验这一假设,我们提出了两个具体目标。在第一个目标中,我们将确定PAQR11 促进动力蛋白介导的高尔基体微型堆积和脑池的带状连接和堆积 创造一个集中的高尔基复合体,驱动顺行的囊泡运输,促进肿瘤细胞的运动。 在第二个目标中,我们将确定异位PAQR11表达促进转移的程度 自发产生的KMLCs。 如果我们的假设是正确的,这些发现将促进我们对KMLC发病机制的理解 细胞获得转移倾向,为该领域的研究人员提供了研究高尔基体的新工具 肺自然微环境中肿瘤细胞的动力学,对 肺腺癌转移的潜在原因,以及研究靶向药物的基础 ZEB1的介体在临床试验中预防KMLC转移。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer.
  • DOI:
    10.1172/jci165863
  • 发表时间:
    2023-04-03
  • 期刊:
  • 影响因子:
    15.9
  • 作者:
    Tan, Xiaochao;Xiao, Guan-Yu;Wang, Shike;Shi, Lei;Zhao, Yanbin;Liu, Xin;Yu, Jiang;Russell, William K.;Creighton, Chad J.;Kurie, Jonathan M.
  • 通讯作者:
    Kurie, Jonathan M.
Use of osteoblast-derived matrix to assess the influence of collagen modifications on cancer cells.
  • DOI:
    10.1016/j.mbplus.2020.100047
  • 发表时间:
    2020-11
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Bota-Rabassedas N;Guo HF;Banerjee P;Chen Y;Terajima M;Yamauchi M;Kurie JM
  • 通讯作者:
    Kurie JM
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jonathan M Kurie其他文献

Jonathan M Kurie的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jonathan M Kurie', 18)}}的其他基金

Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2
阐明赖氨酰羟化酶 2 的促转移胶原蛋白修饰活性
  • 批准号:
    10376870
  • 财政年份:
    2021
  • 资助金额:
    $ 36.6万
  • 项目类别:
A pro-metastatic secretory pathway activated by p53 loss in lung cancer
肺癌中 p53 缺失激活的促转移分泌途径
  • 批准号:
    10277847
  • 财政年份:
    2021
  • 资助金额:
    $ 36.6万
  • 项目类别:
Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2
阐明赖氨酰羟化酶 2 的促转移胶原蛋白修饰活性
  • 批准号:
    10208217
  • 财政年份:
    2021
  • 资助金额:
    $ 36.6万
  • 项目类别:
A pro-metastatic secretory pathway activated by p53 loss in lung cancer
肺癌中 p53 缺失激活的促转移分泌途径
  • 批准号:
    10440513
  • 财政年份:
    2021
  • 资助金额:
    $ 36.6万
  • 项目类别:
A pro-metastatic secretory pathway activated by p53 loss in lung cancer
肺癌中 p53 缺失激活的促转移分泌途径
  • 批准号:
    10656365
  • 财政年份:
    2021
  • 资助金额:
    $ 36.6万
  • 项目类别:
Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2
阐明赖氨酰羟化酶 2 的促转移胶原蛋白修饰活性
  • 批准号:
    10599177
  • 财政年份:
    2021
  • 资助金额:
    $ 36.6万
  • 项目类别:
Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi
高尔基体囊泡生物发生的可操作驱动因素对肺癌生长和转移的调节
  • 批准号:
    10061572
  • 财政年份:
    2019
  • 资助金额:
    $ 36.6万
  • 项目类别:
Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi
高尔基体囊泡生物发生的可操作驱动因素对肺癌生长和转移的调节
  • 批准号:
    10531617
  • 财政年份:
    2019
  • 资助金额:
    $ 36.6万
  • 项目类别:
Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi
高尔基体囊泡生物发生的可操作驱动因素对肺癌生长和转移的调节
  • 批准号:
    10358493
  • 财政年份:
    2019
  • 资助金额:
    $ 36.6万
  • 项目类别:
Regulation of lung cancer metastasis through transcriptional control of the Golgi apparatus
通过高尔基体的转录控制调节肺癌转移
  • 批准号:
    9213276
  • 财政年份:
    2016
  • 资助金额:
    $ 36.6万
  • 项目类别:

相似海外基金

Assessing The Impact of Heparanase and NDST2 Expression on Non-Small Cell Lung Adenocarcinoma Cell Motility
评估乙酰肝素酶和 NDST2 表达对非小细胞肺腺癌细胞运动的影响
  • 批准号:
    449570
  • 财政年份:
    2020
  • 资助金额:
    $ 36.6万
  • 项目类别:
    Studentship Programs
Analysis of cancer metastasis and invasion mechanism using a new lung adenocarcinoma cell line.
使用新的肺​​腺癌细胞系分析癌症转移和侵袭机制。
  • 批准号:
    16K10689
  • 财政年份:
    2016
  • 资助金额:
    $ 36.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Acquisition strategy of tumor-specific markers using established micropapillary pattern pulmonary adenocarcinoma cell line
使用已建立的微乳头模式肺腺癌细胞系获取肿瘤特异性标志物的策略
  • 批准号:
    26460441
  • 财政年份:
    2014
  • 资助金额:
    $ 36.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The antibetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
抗生素药物二甲双胍在体外和体内抑制食管腺癌细胞增殖。
  • 批准号:
    25860540
  • 财政年份:
    2013
  • 资助金额:
    $ 36.6万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
The cell permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferations and can be used as the molecular targeting dru
细胞通透肽抑制胰腺导管腺癌细胞增殖,可作为分子靶向药物
  • 批准号:
    25461969
  • 财政年份:
    2013
  • 资助金额:
    $ 36.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic Research for elucidation of chemo-resistance in mucinous adenocarcinoma cell.
阐明粘液腺癌细胞化疗耐药性的基础研究。
  • 批准号:
    22791532
  • 财政年份:
    2010
  • 资助金额:
    $ 36.6万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
TAS::75 0849::TAS IN THIS PHASE I SBIR THE BREAST CANCER ADENOCARCINOMA CELL LI
TAS::75 0849::TAS 在这一阶段 I SBIR 乳腺癌腺癌细胞 LI
  • 批准号:
    8164743
  • 财政年份:
    2010
  • 资助金额:
    $ 36.6万
  • 项目类别:
Role of Endothelin-1 in osteoblastic bone metastasis produced by a human lung adenocarcinoma cell line
Endothelin-1 在人肺腺癌细胞系产生的成骨细胞骨转移中的作用
  • 批准号:
    19790127
  • 财政年份:
    2007
  • 资助金额:
    $ 36.6万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
CONNEXIN 43 EXPRESSION IN ADENOCARCINOMA CELL LINE
连接蛋白 43 在腺癌细胞系中的表达
  • 批准号:
    6972483
  • 财政年份:
    2004
  • 资助金额:
    $ 36.6万
  • 项目类别:
The mechanisms of highly metastetic capasity in highly metastatic subpopulations of lung adenocarcinoma cell line and these clinical applications
肺腺癌细胞系高转移亚群的高转移能力机制及临床应用
  • 批准号:
    15590831
  • 财政年份:
    2003
  • 资助金额:
    $ 36.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了